---
title: "Hua Xing Capital Holdings: Weigao Blood successfully listed on the main board of the Shanghai Stock Exchange"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/240793908.md"
description: "China Renaissance Holdings announced that its subsidiary, China Renaissance New Economy Fund, has successfully listed Shandong Weigao Blood Purification Products Co., Ltd. on the main board of the Shanghai Stock Exchange, with the stock code 603014. Weigao Blood Purification is a leading enterprise in China's blood purification industry, focusing on the research and development of hemodialysis and peritoneal dialysis. The China Renaissance New Economy Fund led the pre-IPO financing for Weigao Blood Purification in 2022, with a total investment amount of 450 million RMB, demonstrating recognition and confidence in its industry position"
datetime: "2025-05-19T08:52:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/240793908.md)
  - [en](https://longbridge.com/en/news/240793908.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/240793908.md)
generator: "portal-rs"
---

# Hua Xing Capital Holdings: Weigao Blood successfully listed on the main board of the Shanghai Stock Exchange

According to the Zhitong Finance APP, Huaxing Capital Holdings (01911) announced that its subsidiary, as the manager of the Huaxing New Economy Fund, successfully listed its invested company, Shandong Weigao Blood Purification Products Co., Ltd. (Weigao Blood Purification), on the main board of the Shanghai Stock Exchange, with stock code 603014.

Weigao Blood Purification is a leading company in China's blood purification industry with independent core technology. Since its establishment in 2004, the company has continuously invested in research and development and accumulated technical experience, completing a full industrial chain layout for blood purification, including dialyzers, dialysis machines, blood tubing, and peritoneal dialysis solutions, focusing on two strategic directions: hemodialysis and peritoneal dialysis. The Huaxing New Economy Fund led the pre-listing financing for Weigao Blood Purification in 2022, with a total investment amount of 450 million RMB, which fully reflects the group's high recognition and firm confidence in Weigao Blood Purification and its industry-leading position, as well as highlighting the excellent investment research capabilities of the Huaxing New Economy Fund management team

### Related Stocks

- [603014.CN](https://longbridge.com/en/quote/603014.CN.md)
- [22093.HK](https://longbridge.com/en/quote/22093.HK.md)
- [01911.HK](https://longbridge.com/en/quote/01911.HK.md)

## Related News & Research

- [Tekedia Capital invests in Nigeria mining sector via Contisx Exchange unit](https://longbridge.com/en/news/296682229.md)
- [Idealist Celebrates Thirty Years of Helping People Move From Intention to Action](https://longbridge.com/en/news/296683442.md)
- [Episurf accelerates shift to pure-play property company, winds down medtech operations](https://longbridge.com/en/news/296686484.md)
- [Carney Announces Retaliatory Tariffs on U.S. Goods To Take Effect on Sept. 8](https://longbridge.com/en/news/296686300.md)
- [Powerful Growth, Multiple Endorsements Bode Well for Oracle Stock](https://longbridge.com/en/news/296686709.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**